GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG

摘要

FIELD: genetic engineering. ;SUBSTANCE: present invention relates to genetic engineering and medicine, in particular to a gene-cell vesicular therapeutic drug for the treatment of multiple sclerosis and a method for the treatment of multiple sclerosis by transplantation of said drug by single intravenous administration. The preparation according to the invention consists of cytochalasin-induced B micro-vesicules of mesenchymal stromal cells from adipose tissue, previously genetically modified with a recombinant lentivirus containing the nucleotide sequence of the NGF nerve growth factor gene. ;EFFECT: present invention makes it possible to reduce the area of foci of demyelination in the human central nervous system, the number of reactive astrocytes, the level of proinflammatory cytokines in the blood serum of patients with neurogenerative diseases and reduce neuroinflammation in general. ;2 cl, 13 dwg, 1 ex